Oculis SA is a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and lives of patients worldwide.
Products, services, technology
OCS-01 being developed in DME and Post-cataract surgery inflammation;
OCS-02 being developed for Dry Eye;
OCS-03 for back- and front-of-the-eye indications,
OCS-04 and OCS-05 for front-of-the-eye indications